Kesatuan Eropah - Lithuania - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumabas - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antinavikiniai vaistai - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. daugiau informacijos apie žmogaus epidermio augimo faktoriaus receptorių 2 (her2) būklę rasite 5 skyriuje. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. daugiau informacijos apie her2 statusą rasite 5 skyriuje. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Kesatuan Eropah - Lithuania - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antinavikiniai vaistai - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Kesatuan Eropah - Lithuania - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antinavikiniai vaistai - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 ir 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

Kesatuan Eropah - Lithuania - EMA (European Medicines Agency)

biofrontera bioscience gmbh - 5-aminolevulino rūgšties hidrochloridas - keratosis, actinic; carcinoma, basal cell - antinavikiniai vaistai - gydymo aktyvios keratozė lengvas ar vidutinio sunkumo ant veido ir galvos odos (olsen, grade 1 iki 2; žr. skyrių 5. 1) ir lauko cancerization suaugusiems. gydymo paviršutiniškas ir/arba ketaus bazalioma netinka chirurginis gydymas, nes galimas gydymas-susijusi negalavimų ir/arba prastos kosmetikos rezultatus suaugusiems.

Kesatuan Eropah - Lithuania - EMA (European Medicines Agency)

merck europe b.v.  - cetuksimabas - head and neck neoplasms; colorectal neoplasms - antinavikiniai vaistai - erbitux skiriamas pacientams su epidermio augimo faktoriaus receptorių (egfr)-išreikšti, ras laukinio tipo metastazavusiu gaubtinės ir tiesiosios žarnos vėžys:kartu su irinotecan pagrindu chemoterapija;pirmoje eilutėje kartu su folfox;kaip vienas agentas pacientams, kuriems nepavyko oksaliplatinos ir irinotecan pagrįstos terapijos ir kurie netoleruoja irinotecan. dėl išsamesnės informacijos, žr. skyrių 5. erbitux skiriamas pacientams, sergantiems suragėjusių ląstelių vėžys galvos ir kaklo:kartu su radioterapija vietoje progresavusia liga;kartu su platinos pagrindu chemoterapija periodinio ir/arba metastazavusio ligos.

Kesatuan Eropah - Lithuania - EMA (European Medicines Agency)

teva b.v. - topotekanas - ovarian neoplasms; uterine cervical neoplasms; small cell lung carcinoma - antinavikiniai vaistai - topotecan monotherapy is indicated for the treatment of: , patients with metastatic carcinoma of the ovary after failure of first line or subsequent therapy;, patients with relapsed small cell lung cancer [sclc] for whom re-treatment with the first-line regimen is not considered appropriate. , topotecan kartu su cisplatina skiriamas pacientams su karcinomos, gimdos kaklelio periodinis po radioterapijos ir pacientams, sergantiems etape ivb ligos. pacientams, sergantiems prieš sąlyčio su cisplatina būtinas nuolatinis gydymas nemokamai intervalas pagrįsti gydymo derinys.

Lithuania - Lithuania - SMCA (Valstybinė vaistų kontrolės tarnyba)

merial italia s.p.a (italija) - šaldyta vakcina ir skiediklis - vienoje vakcinos dozėje (0,2 ml) yra: gyvų s-706 padermės infekcinės bursos ligos virusų - ne mažiau kaip102,1 tcid50, gyvų fc-126 padermės mareko ligos virusų - ne mažiau kaip 1418 pfu. - sveikiems vienadieniams viščiukams vakcinuoti nuo infekcinės bursos ir mareko ligų.

Lithuania - Lithuania - SMCA (Valstybinė vaistų kontrolės tarnyba)

bros sp.j., ul. karpia 24, 61-619 poznan, lenkija - imidaklopridas, 1-[[][[]](6-chlorpiridin-3-il)metil]-n-nitroimidazolidin-2-iminas; imidaklopridas, 1-[[][[]](6-chlorpiridin-3-il)metil]-n-nitroimidazolidin-2-iminas - veikliosios medžiagos cas nr.: 138261-41-3, eb nr.: 428-040-8, veikliosios medžiagos pavadinimas: imidaklopridas, 1-[[][[]](6-chlorpiridin-3-il)metil]-n-nitroimidazolidin-2-iminas, koncentracija: 10% , veiklioji; veikliosios medžiagos cas nr.: 138261-41-3, eb nr.: 428-040-8, veikliosios medžiagos pavadinimas: imidaklopridas, 1-[[][[]](6-chlorpiridin-3-il)metil]-n-nitroimidazolidin-2-iminas, koncentracija: 10% , veiklioji - insekticidai, akaricidai ir kitų nariuotakojų kontrolės produktai

Lithuania - Lithuania - SMCA (Valstybinė vaistų kontrolės tarnyba)

uab inovacinė firma „mkds“, piliakalnio g. 68, lt-15175 nemenčinė, vilniaus raj. - imidaklopridas, 1-[[][[]](6-chlorpiridin-3-il)metil]-n-nitroimidazolidin-2-iminas - veikliosios medžiagos cas nr.: 138261-41-3, eb nr.: 428-040-8, veikliosios medžiagos pavadinimas: imidaklopridas, 1-[[][[]](6-chlorpiridin-3-il)metil]-n-nitroimidazolidin-2-iminas, koncentracija: 0.9% , veiklioji - insecticidai, akaricidai ir kiti nariuotakojų kontrolės biocidai, skirti naudoti buityje.

Lithuania - Lithuania - SMCA (Valstybinė vaistų kontrolės tarnyba)

uab „profilaktinė dezinfekcija“, aušros al. 53, lt-76302 Šiauliai. - imidaklopridas, 1-[[][[]](6-chlorpiridin-3-il)metil]-n-nitroimidazolidin-2-iminas - veikliosios medžiagos cas nr.: 138261-41-3, eb nr.: 428-040-8, veikliosios medžiagos pavadinimas: imidaklopridas, 1-[[][[]](6-chlorpiridin-3-il)metil]-n-nitroimidazolidin-2-iminas, koncentracija: 2.15% , veiklioji - insekticidai, akaricidai ir kitų nariuotakojų kontrolės produktai